GSK claims lead in Ph3 respiratory drug race

Novartis says that its closely watched asthma and COPD drug QMF149 will be delayed, pushing back a planned filing to 2014. And that means that GSK's next-gen respiratory drug may well get to the marketplace first. GSK has high hopes for Relovair, which is in late-stage development with Theravance. "I'm pretty confident, having seen what's going on elsewhere, we have every chance to now be the first to market with the next-generation of respiratory molecules, in combination, in major markets," GSK Chief Executive Andrew Witty told reporters. Story

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.